Australian Clinical Labs rises as non-COVID revenue rebounds

Australian Clinical Labs

20/02/2023 04:00

** Shares of Australian Clinical Labs  ACL.AX  rise as much
as 9.1% to A$3.23, set to gain most since Dec. 21
    ** ACL says non-COVID revenue continues to strengthen, with
January like-for-like revenue growth of 22% vs a year ago
    ** Pathology firm expects non-COVID revenue to return to
trend growth over time
    ** Continues to believe low, double-digit EBIT margins are
achievable in future
    ** Stock down 0.7% this year, as of last close
 (Reporting by Rishav Chatterjee in Bengaluru)
 ((Rishav.Chatterjee@thomsonreuters.com;))